Neurol. praxi. 2015;16(1):51-53
Treatment of advanced stage Parkinson's disease with intraduodenal levodopa infusions
- Centrum pro diagnostiku a léčbu neurodegenerativních onemocnění, Neurologická klinika LF UP a FN Olomouc
L-DOPA is still considered to be the most effective drug in treating Parkinson's disease. However, its long-term administration is associated with the development of late motor complications that are thought to be due to non-physiological intermittent administration of L-DOPA. Elimination of pulsatile stimulation of dopamine receptors by adjusting a more stable concentration of dopaminergic agents in the plasma and in the striatal region can consequently lead to a significant reduction in these motor complications. We present a case report of a patient with advanced stage Parkinson's disease in whom the introduction of continuous intestinal L-DOPA infusions resulted in alleviating the symptoms of the disease and thus significantly improved the quality of life of the patient.
Keywords: Parkinson's disease, late motor complications, continuous intestinal L-DOPA infusion
Published: January 26, 2015 Show citation
References
- Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001 May; 16(3): 448-458. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother. 2009 Jun; 9(6): 859-867. Bareš M, Kianička B. Mírná kognitivní porucha v léčbě pokročilé Parkinsonovy nemoci - indikována je metylester L-DOPA (Duodopa(R)). Neurol. pro praxi 2014; 15(2): 105-108. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol. 1994 Jul; 36(1): 27-31. Devos D. French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord. 2009 May 15; 24(7): 993-1000. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpérovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Jan; 62(1): 10-15. Kianička B, Žák J, Bareš M. Využití perkutánní endoskopické gastrostomie - přehled indikací, popis techniky a současné trendy v neurologii. Cesk Slov Neurol N 2012; 75/108(2): 165-169. Nyholm D. Duodopa(R) treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord. 2012 Sep; 18(8): 916-929. Nyholm D, Jansson R, Willows T, Remahl IN. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology. 2005 Nov 8; 65(9): 1506-1507. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci. 2008 Dec; 29(Suppl 5): S387-388. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A. LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014 Feb; 13(2): 141-149. Růžička E. Doporučený postup při zahájení léčby Parkinsonovy nemoci. Cesk Slov Neurol N 2009; 72/105(5): 487-490. Scott B, Nyholm D. Patient-perceived retrospective outcome of duodenal levodopa infusion in advanced Parkinson's disease. Eur Neurol J, 2010; 2: 3-10.
Go to original source...